http://www.unboundmedicine.com/medline/ebm/research/denileukin_diftitoxUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19817678/full_citation/Denileukin_diftitox:_a_novel_immunotoxin_Manoukian G, Hagemeister F 
Denileukin diftitox: a novel immunotoxin. [JOURNAL ARTICLE]
Expert Opin Biol Ther 2009 Oct; 9(11):1445-1451.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19707452/full_citation/Denileukin_diftitox_for_the_treatment_of_cutaneous_T_cell_lymphoma_Kaminetzky D, Hymes KB 
Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. [Journal Article]
Biologics 2008 Dec; 2(4):717-24.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19696197/full_citation/How_we_treat_mycosis_fungoides_and_Sezary_syndrome_Prince HM, Whittaker S, Hoppe RT 
How we treat mycosis fungoides and Sezary syndrome. [JOURNAL ARTICLE]
Blood 2009 Aug 20.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19689336/full_citation/Recombinant_immunotoxins_for_the_treatment_of_chemoresistant_hematologic_malignancies_Kreitman RJ 
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. [Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't]
Curr Pharm Des 2009; 15(23):2652-64.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19670725/full_citation/[Regulatory_T_cells_and_their_role_in_antitumor_immune_response][Regulatory T-cells and their role in antitumor immune response] [Journal Article]
Vopr Onkol 2009; 55(3):269-77.
Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19539223/full_citation/Fatal_Hyperacute_Graft_versus_Host_Disease_following_Denileukin_Diftitox_Treatment_for_Recurrent_T_Cell_Lymphoma_after_Allogeneic_Stem_Cell_Transplantation_Khubchandani S, Deeb G, Smiley SL, et al. 
Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation. [Letter]
Biol Blood Marrow Transplant 2009 Jul; 15(7):887-90.
Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19443659/full_citation/Etanercept_mycophenolate_denileukin_or_pentostatin_plus_corticosteroids_for_acute_graft_vs__host_disease:_a_randomized_phase_II_trial_from_the_BMT_CTN_Alousi AM, Weisdorf DJ, Logan BR, et al. 
Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. [JOURNAL ARTICLE]
Blood 2009 May 14.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19433964/full_citation/A_Phase_II_Trial_of_Denileukin_Diftitox_in_Patients_With_Previously_Treated_Advanced_Non_Small_Cell_Lung_Cancer_Gerena-Lewis M, Crawford J, Bonomi P, et al. 
A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer. [JOURNAL ARTICLE]
Am J Clin Oncol 2009 May 8.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19401548/full_citation/Whatever_happened_to_immunotoxins_Research_and_hope_are_still_alive_Holzman DC 
Whatever happened to immunotoxins? Research, and hope, are still alive. [News]
J Natl Cancer Inst 2009 May 6; 101(9):624-5.
Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19367159/full_citation/Novel_therapies_for_peripheral_T_cell_non_Hodgkin's_lymphomas_Cheson BD 
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. [JOURNAL ARTICLE]
Curr Opin Hematol 2009 Apr 13.
Abstract | Full Citation | Find Related Articles